Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026 Annual Meeting

– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML –

– Longer-term Phase 1b data for ziftomenib plus venetoclax and azacitidine in frontline AML support the ongoing Phase 3 KOMET-017 registrational study –

– Exploratory analysis to evaluate ziftomenib clinical activity beyond NPM1-mutated and KMT2A-rearranged subtypes –

– A total of four oral presentations and four posters to highlight the expanding potential of menin inhibition with ziftomenib across AML treatment settings and combinations –

SAN DIEGO and TOKYO, November 4 and 5, 2026 – Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd (TSE: 4151) today announced that eight abstracts related to ziftomenib, including four oral presentations and four posters, have been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting, taking place December 12-15 in New Orleans. Kura and Kyowa Kirin are working together under a strategic collaboration and license agreement to develop and commercialize ziftomenib for the treatment of acute myeloid leukemia (AML) worldwide.

The presentations will include the first clinical results for ziftomenib in combination with the FLT3 inhibitors quizartinib and gilteritinib, longer-term frontline data for ziftomenib plus venetoclax and azacitidine, and an exploratory analysis of ziftomenib activity in molecularly defined AML subtypes beyond *NPM1*-mutated and *KMT2A*-rearranged disease.

“Our strategy is to establish ziftomenib as a preferred menin inhibitor for combination treatment, supported by clinical evidence across complementary therapeutic approaches,” said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. “Our first clinical results with quizartinib and gilteritinib extend this strategy into FLT3 inhibitor combinations. Together with longer-term venetoclax and azacitidine results and studies of additional combinations, these presentations will help define ziftomenib’s potential as a backbone therapy from initial diagnosis through relapsed or refractory disease.”

FLT3 mutations occur in nearly one third of patients with AML and approximately one half of those with an *NPM1* mutation. This overlap makes *NPM1/FLT3* co-mutated AML an important population for ziftomenib combination development.

Two oral presentations will report preliminary safety and clinical activity findings from ziftomenib combinations with FLT3 inhibitors:

- KOMET-007: Ziftomenib plus quizartinib and intensive chemotherapy (7+3) in newly diagnosed *NPM1/FLT3*-ITD co-mutated AML
- KOMET-008: Ziftomenib plus gilteritinib in relapsed or refractory (R/R) *NPM1/FLT3* co-mutated AML

A poster presentation from KOMET-007 will provide longer-term follow-up on response durability, overall survival, and safety with ziftomenib plus venetoclax and azacitidine in patients with newly diagnosed *NPM1*-mutated AML who are ineligible for intensive chemotherapy. These findings support the ongoing global, randomized Phase 3 KOMET-017 registrational study evaluating this combination.

An exploratory analysis from KOMET-001 will describe clinical activity with ziftomenib monotherapy in patients with R/R AML without *NPM1* mutations or *KMT2A* rearrangements whose disease harbors other genomic alterations associated with MEIS1 expression. The findings support further investigation of ziftomenib in additional molecularly defined AML populations.

Two additional oral presentations will feature ziftomenib. The first will report initial results from the PedAL Phase 1 ITCC-101/APAL2020K trial sponsored by Blood Cancer United and Princess Maxima Center evaluating ziftomenib with fludarabine and cytarabine in pediatric R/R acute leukemia. The second will present preclinical findings from additional subsets of menin-associated leukemias.

All eight abstracts related to ziftomenib, including those from investigator-sponsored trials, are available on the ASH website.

Select 2026 ASH Presentation Details

Abstract Title	Abstract Number	Presentation Details
Ziftomenib combined with gilteritinib for relapsed/refractory *NPM1* and *FLT3* co-mutated acute myeloid leukemia (AML): First results from the KOMET-008 phase 1 study	Oral Presentation #66	Session 617 December 12 10:45 a.m. CST Great Hall AD
Ziftomenib combined with intensive induction (7+3) and quizartinib for newly diagnosed *NPM1*-m and *FLT3*-ITD+ acute myeloid leukemia (AML): Preliminary results from KOMET-007	Oral Presentation #902	Session 617 December 14 3:00 p.m. CST Great Hall BC
Ziftomenib combined with venetoclax/azacitidine in newly diagnosed *NPM1*-m acute myeloid leukemia (AML): Long-term results from KOMET-007	Poster Presentation #5192	Session 617 December 14 6:00-8:00 p.m. CST Hall F

Clinical activity of ziftomenib extends beyond *NPM1*-mutated and *KMT2A*-rearranged acute myeloid leukemia (AML) into *MEIS1*-associated genomic subtypes	Poster Presentation #5190	Session 617 December 14 6:00-8:00 p.m. CST Hall F
Ziftomenib combined with fludarabine and cytarabine in pediatric relapsed/refractory acute leukemia with *KMT2A* rearrangements, *NUP98* rearrangements, or *NPM1* mutations: First results of the phase 1 ITCC-101/APAL2020K trial (NCT06376162)	Oral Presentation #666	Session 616 December 13 5:45 p.m. CST Hall B
SETBP1-mutant leukemias depend on MENIN-associated KMT2A chromatin complexes to maintain leukemogenic transcriptional programs	Oral Presentation #101	Session 636 December 12 10:30 a.m. CST Hall C

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura's pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory *NPM1*-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

About Kyowa Kirin
Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, Kyowa Kirin has invested in drug discovery and biotechnology innovation for more than 70 years and is currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology and rare diseases. A shared commitment to Kyowa Kirin's values, to sustainable growth, and to making people smile unites Kyowa Kirin across the globe. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.

About KOMZIFTI® (ziftomenib)
KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible *NPM1* mutation who have no satisfactory alternative treatment options.
Ziftomenib is in development for the treatment of frontline and R/R AML harboring *NPM1* mutations, *KMT2A* translocations and *FLT3* mutations, with the potential to be combined with approved therapies and benefit a broad spectrum of patients.